Leonard Post Sells 1,000 Shares of CG Oncology (NASDAQ:CGON) Stock

CG Oncology, Inc. (NASDAQ:CGON) Director Leonard Post sold 1,000 shares of the business’s stock in a transaction that occurred on Thursday, June 4th. The shares were sold at an average price of $54.50, for a total value of $54,500.00. Following the completion of the sale, the director owned 1,000 shares in the company, valued at $54,500. The trade was a 50.00% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link.

CG Oncology Stock Performance

NASDAQ CGON traded down $2.37 during trading on Friday, hitting $53.72. The stock had a trading volume of 954,021 shares, compared to its average volume of 1,194,295. The company has a market capitalization of $4.74 billion, a PE ratio of -23.06 and a beta of 0.31. The company’s 50-day moving average price is $66.22 and its two-hundred day moving average price is $56.04. CG Oncology, Inc. has a 12 month low of $23.65 and a 12 month high of $75.50.

CG Oncology (NASDAQ:CGON) last released its earnings results on Friday, May 8th. The company reported ($0.71) EPS for the quarter, missing the consensus estimate of ($0.58) by ($0.13). The business had revenue of $1.08 million during the quarter, compared to analysts’ expectations of $0.45 million. As a group, equities analysts anticipate that CG Oncology, Inc. will post -2.89 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of brokerages have recently issued reports on CGON. Wolfe Research began coverage on CG Oncology in a research note on Tuesday, May 19th. They set a “peer perform” rating on the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of CG Oncology in a research note on Monday, April 20th. Wall Street Zen cut CG Oncology from a “hold” rating to a “sell” rating in a research note on Saturday, April 25th. HC Wainwright reiterated a “buy” rating and set a $100.00 price objective on shares of CG Oncology in a research note on Monday, May 18th. Finally, JPMorgan Chase & Co. upped their price objective on CG Oncology from $91.00 to $96.00 and gave the stock an “overweight” rating in a research note on Monday, May 11th. Eleven research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, CG Oncology currently has a consensus rating of “Moderate Buy” and a consensus price target of $81.73.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the business. NFSG Corp acquired a new position in shares of CG Oncology during the 1st quarter worth approximately $34,000. Whittier Trust Co. of Nevada Inc. acquired a new position in shares of CG Oncology during the 4th quarter worth approximately $27,000. Comerica Bank increased its holdings in shares of CG Oncology by 100.4% during the 4th quarter. Comerica Bank now owns 1,028 shares of the company’s stock worth $43,000 after acquiring an additional 515 shares during the last quarter. Fifth Third Bancorp acquired a new position in shares of CG Oncology during the 1st quarter worth approximately $74,000. Finally, KBC Group NV acquired a new position in shares of CG Oncology during the 1st quarter worth approximately $78,000. 26.56% of the stock is owned by institutional investors and hedge funds.

About CG Oncology

CG Oncology, Inc (NASDAQ: CGON) is a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibody-based immunotherapies for the treatment of solid tumor cancers. The company leverages a platform-driven approach to identify and optimize antibody candidates that engage key immune checkpoints and co-stimulatory pathways within the tumor microenvironment. Its pipeline encompasses multiple preclinical programs alongside early-phase clinical trials designed to assess safety, dosing and preliminary anti-tumor activity.

Headquartered in South San Francisco, California, CG Oncology conducts clinical research primarily in the United States, collaborating with leading academic medical centers and contract research organizations to advance its lead candidates.